Purisys Cannabinoid Ingredients Descheduled by U.S. Drug Enforcement Agency

Ultra-High Purity, Pharmaceutical-Grade CBD and Other Derivatives Are Available for Clinical Study and Broad Range of Pharmaceutical and Consumer Products Athens, GA 21, November 2019: Purisys, LLC, the leader in ultra-high purity cannabinoids, announced today that the U.S. Drug Enforcement Agency has removed its Cannabidiol (CBD) from Schedule I of ...
Read More

Botanix announces cannabidiol supply agreement with Purisys

Key highlights Botanix announces execution of an API Supply Agreement with Purisys, the industry’s leader in ultra-pure, pharmaceutical-grade cannabidiol technology New arrangement secures supply of synthetic cannabidiol for Botanix’s expanding demand and future commercial supplies Agreement executed as Botanix anticipates top line data from BTX 1503 Phase 2 study, to ...
Read More

Purisys at CPhI 2019

Visit us at stand 40F41 at CPhI Worldwide in Frankfurt, Germany to find out more about the latest products anddevelopments from Purisys. To find out more, go to: ...
Read More